Zhang Q, Xu HF, Song WY, Zhang PJ, Song YB. Potential microRNA panel for the diagnosis and prediction of overall survival of hepatocellular carcinoma with hepatitis B virus infection. World J Gastrointest Oncol 2020; 12(4): 383-393 [PMID: 32368317 DOI: 10.4251/wjgo.v12.i4.383]
Corresponding Author of This Article
Yong-Bo Song, PharmD, Associate Professor, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. songyongbo@syphu.edu.cn
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2020; 12(4): 383-393 Published online Apr 15, 2020. doi: 10.4251/wjgo.v12.i4.383
Potential microRNA panel for the diagnosis and prediction of overall survival of hepatocellular carcinoma with hepatitis B virus infection
Qi Zhang, Hai-Feng Xu, Wen-Yue Song, Peng-Jun Zhang, Yong-Bo Song
Qi Zhang, Wen-Yue Song, Yong-Bo Song, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning Province, China
Hai-Feng Xu, Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Zhang Q, Xu HF, Song YB and Zhang PJ designed the study; Zhang Q performed the research; Xu HF and Song WY analyzed the data; Zhang Q and Xu HF wrote the paper; Song YB and Zhang PJ revised the manuscript for final submission; Zhang Q and Xu HF contributed equally to this study; Song YB and Zhang PJ are the co-corresponding authors.
Supported bythe National Key R&D Program of China, No. 2016YFC0106604.
Institutional review board statement: The study was reviewed and approved by the Peking University Cancer Hospital & Institute review board. All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yong-Bo Song, PharmD, Associate Professor, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. songyongbo@syphu.edu.cn
Received: December 22, 2019 Peer-review started: December 22, 2019 First decision: January 19, 2020 Revised: February 6, 2020 Accepted: March 23, 2020 Article in press: March 23, 2020 Published online: April 15, 2020 Processing time: 115 Days and 0.6 Hours
ARTICLE HIGHLIGHTS
Research background
The vast majority of liver cancer cases in China are closely related to hepatitis B virus (HBV) infection, but there are few studies on the changes of microRNAs (miRNA) expression in the progression from HBV infection to hepatoma.
Research motivation
In this study, TaqMan Low Density Array and real time quantitative polymerase chain reaction were used to characterize the profile of miRNAs in chronic hepatitis B, HCC and normal control tissues.
Research objectives
This study aimed to explore the role of miRNAs in the progression of HBV infection to cirrhosis and even to liver cancer.
Research methods
The authors screened differentially expressed miRNAs in 40 HBV cirrhosis, 40 normal and 15 HCC tissues. Authors calculated the area under the receiver-operating-characteristic curves.
Research results
The levels of miR-375, miR-122 and miR-143 were significantly lower in HBV cirrhosis tissues, while miR-224 was significantly higher than in the controls. The area under the curves of the receiver-operating-characteristic curve for the 4-miRNA panel was 0.991. Patients with a lower expression level of miR-224 or higher expression levels of miR-375, miR-122 and miR-143 had longer overall survival.
Research conclusions
The miR-375, miR-122, miR-143 and miR-224 may be helpful for early diagnosis of HBV infection, HBV cirrhosis, and prediction of its overall survival.
